ClinicalTrials.gg
RecruitingNCT06522984Updated Jul 26, 2024

Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid

An interventional study of Tranexamic acid injection in Refractory Melasma, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Egymedicalpedia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing Tranexamic Acid in Melanosis — 6 open to participants now, 7 under way, 2 of them phase 3. Tranexamic Acid · Melanosis.

Planned enrollment
10th of 16
45 · median 52
Started
2024
with 2 others
No phase
4 of 16
2 open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Egymedicalpedia

Among the 16 studies testing Tranexamic Acid in Melanosis, this one is the 10th largest by planned enrollment, is one of 3 that started in 2024, is one of 4 with no phase, and was the 11th registered.

Melanosis

170 studies on the registry are indexed under Melanosis; 46 are open to participants now.

Browse Melanosis studies →

Open to participants now

6 of the 16 studies testing Tranexamic Acid in Melanosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Melanosis studies recruiting now, 8 (42%) set no upper age limit and 11 (58%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Tranexamic Acid in Melanosis, or all of them as a file.
02

Study summary

Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes.

Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. Compared to men, women are more likely to be affected.

Read the detailed description

Melasma is more common in people with dark complexions and Fitzpatrick skin types III IV.Depending on ethnicity and region, melasma prevalence might vary from 8.8% to 40%. The cause of melasma is still unknown in the meantime.

Numerous elements, including genetics, sunshine, endocrine stimulation, oxidative conditions,pregnancy, exogenous hormons,and morphofunctional changes, may have a role in the development of the disease.

Since melasma is a common skin condition affecting mostly pregnant women and those on hormonal birth control, it is known as the "mask of pregnancy,

Treatment for melasma remains a challenge, with substantial psychosocial ramifications. Many factors, including variability in clinical presentation and responsiveness to treatment between genders, skin phototypes, and ethnicities, can affect treatment efficacy. None of variety methods have been sufficiently effective to be considered the gold standard.

Hydroquinone (HQ) has historically been the most studied topical agent in the treatment of melasma. HQ is a hydroxyphenolic compound that inhibits the conversion of dopa to melanin by the inhibition of tyrosinase; it also inhibits RNA and DNA synthesis of melanocytes and degrades melanosomes.

Tranexamic acid (TXA) is an antifibrinolytic drug that has been used off-label for the treatment of melasma, as an oral or intradermal injection.

TXA is a lysine-derived amino acid with anti-inflammatory effects that prevents ultraviolet (UV)-induced skin pigmentation by inhibiting attachment of plasminogen to keratinocytes and activation of plasmin. Plasmin stimulates melanogenesis by conversionof arachidonic acid to prostaglandin and leukotriene. On the other hand, plasmin increases the level of melanogenic factors.

Laser therapy is a unique ablative modality that might potentially increase the penetration of medications applied topically by destroying the SC, epidermal, and dermal layers of the skin in a predictable and controlled manner.

The Fractional erbiumdoped yttrium aluminum garnet (Er: YAG) laser has a wavelength of 2,940 nm and is strongly absorbed by water in the epidermis. It exerts its ablation effect with minimal penetration depth and minimal heat generation and therefore minimal thermal damage.

03

Conditions studied

  • Refractory Melasma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes with melasma.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Administration of oral pills or any phototoxic drug within 1 month prior to study
  • Patients with a history of thrombosis, abnormal bleeding profile, known to TA or HQ, and endocrinal disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Group A

    About 15 cases will receive sessions with fractional Er: YAG laser every 3 weeks followed by application of topical 4% (HQ) cream.

    Drug: Tranexamic acid injection

  • Active comparator
    Group B

    About 15 cases will receive sessions of intradermal injection of tranexamic acid on the melasma site every 3 weeks concurrently with the application of topical 4% HQ cream every night. The injections will be done using an insulin syringe with a dilution of the tranexamic acid

    Drug: Tranexamic acid injection

  • Active comparator
    Group C

    About 15 cases will receive oral tranexamic acid 500mg tablet once daily for three months. And will also be asked to apply a thin layer of topical HQ 4% cream on the hyperpigmented areas once every night.

    Drug: Tranexamic acid injection

Interventions

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    to evaluate and compare efficacy of: * Fractional Er: YAG laser combined with topical hydroquinone. * Intradermal injection of tranexamic acid combined with topical hydroquinone cream. * Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.

    Also known as: Fractional erbium YAG laser

06

What researchers measure

Primary outcomes

  1. Refractory Melasma Treatment combination with topical hydroquinone

    to detect the treatment response by YAG laser vs intradermal and systemic tranexamic acid by using The MASI index ( MASI is an index designed to quantify the severity of melasma during therapy).

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

Of 53 interventional studies with no phase under Melanosis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 26, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 10, 2025
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06522984
Lead sponsor
Egymedicalpedia
Collaborators
Aswan University
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Jun 1, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 10, 2025 (estimated)
Last update
Jul 26, 2024

Study contacts

Heba Allah Mohamed Mustafa, Resident
Contact
HebaAllah1704336@aswu.edu.eg
+201151182890
Moustafa Adam Ali El Taieb, professor
Contact
moustafa.eltaib@aswu.edu.eg
+201092991101
Moustafa Adam Ali El Taieb, Professor
study chair · Dermatology, Venereology and Andrology.Faculty of Medicine, Aswan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion